Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation

Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation

Abstract Recent development of new immune checkpoint inhibitors has been particularly successfully in cancer treatment, but still the majority patients fail to benefit. Converting resistant tumors to immunotherapy sensitive will provide a significant improvement in patient outcome. Here we identify...

Full description

Bibliographic Details
Main Authors: Cang Li, Zhengyu Wang, Licheng Yao, Xingyu Lin, Yongping Jian, Yujia Li, Jie Zhang, Jingwei Shao, Phuc D. Tran, James R. Hagman, Meng Cao, Yusheng Cong, Hong-yu Li, Colin R. Goding, Zhi-Xiang Xu, Xuebin Liao, Xiao Miao, Rutao Cui
Format: Article
Language:English
Published: Nature Portfolio 2024-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-46422-5

Internet

https://doi.org/10.1038/s41467-024-46422-5

Similar Items